BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 2160323)

  • 21. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model.
    Yano T; Pinski J; Szepeshazi K; Milovanovic SR; Groot K; Schally AV
    Prostate; 1992; 20(4):297-310. PubMed ID: 1351672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells.
    Segal-Abramson T; Kitroser H; Levy J; Schally AV; Sharoni Y
    Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2336-9. PubMed ID: 1312718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitory effect of a highly potent antagonist of LH releasing hormone (SB-75) on the pituitary gonadal axis in the intact and castrated rat.
    Ayalon D; Farhi Y; Comaru-Schally AM; Schally AV; Eckstein N; Vagman I; Limor R
    Neuroendocrinology; 1993 Aug; 58(2):153-9. PubMed ID: 8264861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies.
    Schally AV; Srkalovic G; Szende B; Redding TW; Janaky T; Juhasz A; Korkut E; Cai RZ; Szepeshazi K; Radulovic S
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1061-7. PubMed ID: 1981009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones.
    Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1984 Jan; 81(1):248-52. PubMed ID: 6141560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blockade of the LH response induced by the agonist D-Trp-6-LHRH in rats by a highly potent LH-RH antagonist SB-75.
    Pinski J; Yano T; Miller G; Schally AV
    Prostate; 1992; 20(3):213-24. PubMed ID: 1533453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of growth of a prolactin and growth hormone-secreting pituitary tumor in rats by D-tryptophan-6 analog of luteinizing hormone-releasing hormone.
    Torres-Aleman I; Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1985 Feb; 82(4):1252-6. PubMed ID: 2858096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
    Yano T; Pinski J; Szepeshazi K; Halmos G; Radulovic S; Groot K; Schally AV
    Cancer; 1994 Feb; 73(4):1229-38. PubMed ID: 8313327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma.
    Srkalovic G; Szende B; Redding TW; Groot K; Schally AV
    Proc Soc Exp Biol Med; 1989 Dec; 192(3):209-18. PubMed ID: 2574866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.
    Korkut E; Bokser L; Comaru-Schally AM; Groot K; Schally AV
    Proc Natl Acad Sci U S A; 1991 Feb; 88(3):844-8. PubMed ID: 1992476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone.
    Yano T; Pinski J; Radulovic S; Schally AV
    Proc Natl Acad Sci U S A; 1994 Mar; 91(5):1701-5. PubMed ID: 8127868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment with luteinizing-hormone-releasing hormone antagonist sb-75 decreases levels of epidermal growth-factor receptor and its messenger-RNA in ov-1063 human epithelial ovarian-cancer xenografts in nude-mice.
    Shirahige Y; Cook C; Pinski J; Halmos G; Nair R; Schally A
    Int J Oncol; 1994 Nov; 5(5):1031-5. PubMed ID: 21559676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination.
    Szepeshazi K; Milovanovic S; Lapis K; Groot K; Schally AV
    Breast Cancer Res Treat; 1992; 21(3):181-92. PubMed ID: 1355375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of experimental ovarian carcinoma with monthly injection of the agonist D-Trp-6-LH-RH: a preliminary report.
    Pour PM; Redding TW; Paz-Bouza JI; Schally AV
    Cancer Lett; 1988 Jul; 41(1):105-10. PubMed ID: 2968836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix.
    Halmos G; Schally AV; Kahan Z
    Int J Oncol; 2000 Aug; 17(2):367-73. PubMed ID: 10891548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of streptozotocin-induced islet cell tumors and N-nitrosobis(2-oxopropyl)amine-induced pancreatic exocrine tumors in Syrian hamsters by exogenous insulin.
    Pour PM; Kazakoff K; Carlson K
    Cancer Res; 1990 Mar; 50(5):1634-9. PubMed ID: 2154330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma.
    Srkalovic G; Wittliff JL; Schally AV
    Cancer Res; 1990 Mar; 50(6):1841-6. PubMed ID: 2155060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the in vitro and in vivo activity of the L-, D,L- and D-Cit6 forms of the LH-RH antagonist Cetrorelix (SB-75).
    Pinski J; Schally AV; Yano T; Groot K; Srkalovic G; Serfozo P; Reissmann T; Bernd M; Deger W; Kutscher B
    Int J Pept Protein Res; 1995 May; 45(5):410-7. PubMed ID: 7591480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone.
    Reissmann T; Hilgard P; Harleman JH; Engel J; Comaru-Schally AM; Schally AV
    J Cancer Res Clin Oncol; 1992; 118(1):44-9. PubMed ID: 1530849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.